Corbus drug succeeds in mid-stage scleroderma study, shares surge

(Reuters) - Corbus Pharmaceuticals Holdings Inc said its only drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis, an incurable autoimmune condition caused by abnormal growth of connective tissue.

Source: Reuters: Health - November 14, 2016 Category: Consumer Health News Tags: healthNews Source Type: news